公开(公告)号：US20240159751A1

公开(公告)日：2024-05-16

申请号：US18514032

申请日：2023-11-20

申请人： Kyoto University ,  KM Biologics Co., Ltd.

发明人： Koichiro HATA ,  Shinji Uemoto ,  Hirofumi Hirao ,  Toyonari Kubota

IPC分类号： G01N33/573 ,  A61K38/48 ,  G01N33/576

CPC分类号： G01N33/573 ,  A61K38/4886 ,  G01N33/576 ,  G01N2333/96494 ,  G01N2800/08 ,  G01N2800/085

摘要： New use of ADAMTS13 in the clinical filed is provided. The use of ADAMTS13 as a biomarker for monitoring the onset of liver damage, hepatic ischemia/reperfusion injury or the liver function after liver transplantation: a method of testing liver damage, a method of testing hepatic ischemia/reperfusion injury, or a method of testing the liver function after liver transplantation, each of the methods comprising measuring or monitoring the ADAMTS13 activity in a sample from a mammal; an agent for treating diseases selected from the group consisting of liver damage, hepatic ischemia/reperfusion injury and hepatic dysfunction after liver transplantation, which comprises ADAMTS13 or a mutant of ADAMTS13 as an effective ingredient.

公开(公告)号：US20240012009A1

公开(公告)日：2024-01-11

申请号：US18035549

申请日：2021-11-05

申请人： KEYINTEL MEDICAL INC.

发明人： Florence Wing Ling Tsui ,  Aifeng Lin ,  Kenneth Phillip Henry Pritzker ,  Robert Davies Inman

IPC分类号： G01N33/68 ,  C07K16/24 ,  A61K31/496 ,  A61K31/4418 ,  A61P19/02 ,  A61P29/00

CPC分类号： G01N33/6893 ,  C07K16/241 ,  C07K16/244 ,  A61K31/496 ,  A61K31/4418 ,  A61P19/02 ,  A61P29/00 ,  G01N2800/102 ,  G01N2800/065 ,  G01N2333/5412 ,  G01N2333/96494 ,  C07K2317/76

摘要： Methods of assessing, monitoring and/or predicting clinical disease activity, treatment response, disease progression, and/or active repair for chronic inflammatory disease such as axial spondyloarthritis are provided based on the level and/or pattern of LCN2, LCN2-MMP9 and/or OSM.

公开(公告)号：US20240011983A1

公开(公告)日：2024-01-11

申请号：US18016384

申请日：2021-07-21

申请人： Progentec Diagnostics, Inc. ,  Oklahoma Medical Research Foundation

发明人： Melissa MUNROE ,  Judith JAMES ,  Eldon JUPE ,  Mohan PURUSHOTHAMAN

IPC分类号： G01N33/564

CPC分类号： G01N33/564 ,  G01N2333/96494 ,  G01N2333/54 ,  G01N2333/525 ,  G01N2800/104

摘要： A method for determining whether a Systemic lupus erythematosus (SLE) patient is undergoing a pre-flare event, the method comprising obtaining a blood, serum, plasma, or saliva sample from the SLE patient; assessing a level of expression for each of a plurality of biomarkers, the plurality of biomarkers comprising OPN, MCP-1/CCL2, MCP-3/CCL7, IL-17A, TNFRII, TNFRI, IL-4, IL-5, BLyS, TNFα, and IL-7; determining a Lupus Flare Risk Prediction Index (LFPI) for the patient based upon the level of expression for each of a plurality of biomarkers; and based upon the LFPI, determining whether the patient is undergoing a pre-flare event.

公开(公告)号：US20230417769A1

公开(公告)日：2023-12-28

申请号：US18243159

申请日：2023-09-07

申请人： KONINKLIJKE PHILIPS N.V.

发明人： Bart Jacob BAKKER ,  Marinus Karel Johannes DE JAGER ,  Amir Hussein RMAILE ,  Philip PRESHAW ,  John TAYLOR

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/4753 ,  G01N2333/96494 ,  G01N2800/18

摘要： Disclosed is an in vitro method for assessing whether a human subject has periodontitis. The method comprises detecting, in a sample of saliva from said subject, the concentrations of the proteins Hepatocyte Growth Factor (HGF) and Matrix Metalloproteinase 8 (MMP-8). Based on the concentrations determined, and adding age, and possibly other demographic markers such as sex and/or BMI, a testing value reflecting the joint concentrations is determined for said proteins, in combination with one or more demographic markers. The testing value is compared with a threshold value. The threshold reflects in the same manner the joint concentrations and the age, and possibly other demographic markers, as associated with periodontitis and may be seen as an upper limit of testing values as seen in a population of subjects without periodontitis. Thereby a testing value at or above the threshold value is indicative for periodontitis in said subject.

公开(公告)号：US20180305769A1

公开(公告)日：2018-10-25

申请号：US15913633

申请日：2018-03-06

申请人： Varian Medical Systems, Inc.

发明人： Renate Parry

IPC分类号： C12Q1/6886 ,  A61K31/337 ,  A61K31/7115 ,  A61K33/24 ,  A61K39/395 ,  A61N5/10 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  A61K31/337 ,  A61K31/7115 ,  A61K33/24 ,  A61K39/3955 ,  A61N5/1064 ,  A61N2005/1098 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N2333/4703 ,  G01N2333/4712 ,  G01N2333/70585 ,  G01N2333/70596 ,  G01N2333/90203 ,  G01N2333/96494 ,  G01N2400/40

摘要： The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.

公开(公告)号：US20180196048A1

公开(公告)日：2018-07-12

申请号：US15322845

申请日：2015-07-02

申请人： BIONOMICS LIMITED

发明人： Gabriel KREMMIDIOTIS ,  Annabell Francis LESKE

IPC分类号： G01N33/574 ,  A61K31/343 ,  A61K45/06 ,  A61P35/00

CPC分类号： G01N33/574 ,  A61K31/343 ,  A61K31/436 ,  A61K45/06 ,  A61P35/00 ,  G01N2333/475 ,  G01N2333/805 ,  G01N2333/96494 ,  G01N2800/52 ,  A61K2300/00

摘要： The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

公开(公告)号：US09914955B2

公开(公告)日：2018-03-13

申请号：US14911821

申请日：2014-08-12

申请人： Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk

发明人： Michal Stawarski ,  Jakub Wlodarczyk ,  Leszek Kaczmarek

IPC分类号： A61K39/00 ,  C07K14/00 ,  C07K16/00 ,  C12Q1/37 ,  G01N33/542

CPC分类号： C12Q1/37 ,  C07K14/00 ,  C07K2319/50 ,  C07K2319/60 ,  G01N33/542 ,  G01N2333/96494

摘要： The present invention relates to a genetically encoded FRET-based biosensor to monitor the activity of matrix metalloproteinase 9 (MMP-9). MMP-9 is an extracellular acting endopeptidase implicated in both physiological and pathological processes. A genetically encoded FRET biosensor anchored in the cellular membrane allows studying the proteolytic activity of MMP-9 with high spatiotemporal resolution at the exact region of MMP-9 action on the cell. Applicability of the biosensor, both in vitro and in vivo in living cells, has been demonstrated by ratiometric analysis of cleavage of the biosensor by a purified auto-activating mutant of MMP-9.

公开(公告)号：US09892229B2

公开(公告)日：2018-02-13

申请号：US14435991

申请日：2013-10-16

申请人： RANDOX LABORATORIES LTD.

发明人： Mark William Ruddock ,  Cherith N. Reid ,  Kate E. Williamson ,  Frank Emmert-Streib ,  John V. Lamont ,  Peter Fitzgerald

IPC分类号： G01N33/48 ,  G06F19/18 ,  G01N33/574 ,  G06F19/24 ,  G06F19/00 ,  G06G7/58

CPC分类号： G06F19/18 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2333/4737 ,  G01N2333/4742 ,  G01N2333/475 ,  G01N2333/485 ,  G01N2333/523 ,  G01N2333/525 ,  G01N2333/5406 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/545 ,  G01N2333/55 ,  G01N2333/70578 ,  G01N2333/70596 ,  G01N2333/7151 ,  G01N2333/7452 ,  G01N2333/928 ,  G01N2333/96433 ,  G01N2333/96494 ,  G01N2333/988 ,  G01N2400/00 ,  G06F19/00 ,  G06F19/24 ,  G16H50/30

摘要： The invention provides a method of defining the likelihood of a subject having bladder cancer, comprising the steps of: (A) assessing the subject's likelihood of having bladder cancer by: i. identifying at least one sub-population group appropriate to the subject; ii. determining the level of one or more biomarkers selected according to the sub-population group in a sample obtained from the subject; iii. inputting each of the biomarker values into an algorithm to produce an output value; and iv. correlating the output value with the likelihood of the subject having bladder cancer, wherein the sub-population group is selected according to smoking habits, gender, presence/absence of stone disease, history of benign prostate enlargement (BPE) or prescription of anti-hypertensive, anti-platelet and/or anti-ulcer medication, and (B) determining the subject's stratified risk level of serious disease by: v. determining the level of one or more biomarkers specific for one or more risk classifiers defined using Random Forest Classifiers (RFC), logistic regression or another appropriate systems biology or statistical approach in a sample obtained from the subject, vi. inputting each of the biomarker values into an algorithm or algorithms to produce an output value; and vii. correlating the output value with a stratified risk level of underlying serious disease, wherein the likelihood of having bladder cancer is combined with the stratified risk level of having serious disease, wherein the risk of having bladder cancer and/or serious disease is categorized as: high-risk bladder cancer requiring immediate cystoscopy; low-risk bladder cancer requiring urgent cystoscopy; high-risk control requiring close evaluation and further investigation; or low-risk control requiring primary care monitoring.

公开(公告)号：US09804175B2

公开(公告)日：2017-10-31

申请号：US14542757

申请日：2014-11-17

申请人： New York University

发明人： Mukundan Attur ,  Steven B. Abramson

IPC分类号： G01N33/00 ,  C12Q1/00 ,  G01N33/74 ,  C12Q1/68

CPC分类号： G01N33/74 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/475 ,  G01N2333/52 ,  G01N2333/545 ,  G01N2333/964 ,  G01N2333/96494 ,  G01N2800/105 ,  G01N2800/56

摘要： This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject.

公开(公告)号：US20170292953A1

公开(公告)日：2017-10-12

申请号：US15358560

申请日：2016-11-22

申请人： Children's Medical Center Corporation

发明人： Marsha A. Moses ,  Li Yan

IPC分类号： G01N33/573 ,  G01N33/574

CPC分类号： G01N33/573 ,  C12Q1/37 ,  G01N33/574 ,  G01N33/57434 ,  G01N33/57488 ,  G01N2333/96486 ,  G01N2333/96494 ,  G01N2333/99 ,  G01N2550/00

摘要： Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs.